Why weight changes in menopause, and what hormone therapy and GLP-1s do

Partly because of age, and the transition mainly changes body composition. The Menopause Society's 2022 position statement puts average weight gain in midlife at about 1.5 lb a year and says it levels off about two years after the final period [4]. In SWAN, which scanned 1,246 women with DXA over the years around their final period, weight rose about 0.3% a year during the transition, and the rate did not speed up when the transition began [1].

What did change was the mix. Fat gain rose from 1.0% to 1.7% a year at the start of the transition, and lean mass, which had been growing slightly, started to fall. Across the roughly three and a half years of the transition that added up to about 6% more fat (around 1.6 kg) and 0.5% less lean mass; both changes flattened out about two years after the final period [1].

Fat shifts from the hips and thighs toward the abdomen around menopause, and the Menopause Society notes that this central shift is seen even after adjusting for age, total body fat and physical activity [4]. In a four-year study of 156 women scanned by CT, all groups gained fat under the skin of the belly, but only the women who became postmenopausal had a significant rise in visceral fat, the fat around the organs: from 88.0 to 97.5 cm² on average [3].

A later SWAN analysis of 380 women followed for a median of almost 12 years found visceral fat grew about 6.2% a year during the transition, against no significant change before it and about 1.5% a year after; over the 12 years around the final period it rose 32.5% in total [2]. Waist and hip measurements changed far less than the scans showed, so a tape measure can miss much of the shift [2]. The same four-year CT study also found that energy used during sleep fell more in the women who became postmenopausal (7.9% against 5.3%) [3].

No. A Cochrane review of 28 randomized trials with 28,559 women found hormone therapy made no difference to body weight: +0.03 kg for estrogen alone and +0.04 kg for estrogen with a progestogen, compared with no treatment, and it did not prevent the weight gain of menopause [5]. The Menopause Society says hormone therapy may slightly reduce the build-up of belly fat during the transition, but calls the effect small [4].

Hormone therapy is prescribed for symptoms such as hot flashes and night sweats. A 2026 position statement from the Spanish Menopause Society adds that the link between hormone therapy and larger weight loss on semaglutide is only a hypothesis, and does not justify starting hormone therapy to lose more weight [11].

The evidence so far is observational; we found no randomized trial of the combination. At Mayo Clinic, a review of health records for 106 postmenopausal women on semaglutide found that the 16 also using hormone therapy had lost 16% of their body weight on average at 12 months, against 12% for the 90 who were not [6]. The authors list the limits themselves: it is retrospective and cannot establish cause and effect, it is small, and the women were mostly White, college-educated and without financial strain.

A second Mayo team looked at tirzepatide. In its conference abstract (ENDO 2025), 40 women on hormone therapy, matched to 80 who were not, lost a median 17% against 14% over a median of 18 months [7]; the full study was published in 2026 in The Lancet Obstetrics, Gynaecology & Women's Health [8]. It is also retrospective.

In the trials, menopausal stage made little difference to how these drugs worked. In a post hoc analysis of the SURMOUNT-1 trial (most authors employed by the drug's maker), average weight loss on tirzepatide was 26% before menopause, 23% in perimenopause and 23% after menopause, against 2 to 3% on placebo [9]; a small four-month study found similar loss on semaglutide in post- and premenopausal women [10]. These are trial averages, not a prediction for any one person. What GLP-1s cost, by route, is on GLP-1 cost by route, and platforms that handle both are in the menopause platform comparison.

FDA labeling for systemic estrogen lists these as reasons not to use it: abnormal genital bleeding with no known cause; current or past breast cancer; estrogen-dependent cancer; a current or past blood clot in the legs or lungs; a current or past stroke or heart attack; liver disease; known clotting disorders; and an allergic reaction to the product [12]. This is why the self-check sends anyone with one of these straight to an in-person doctor.

In February 2026 the FDA removed the statements on cardiovascular disease, breast cancer and probable dementia from the boxed warning on menopausal hormone therapy labels [13]; the contraindications above did not change.

The major reviews say there is not enough evidence to support them over FDA-approved products. A 2020 National Academies report found insufficient evidence for the overall clinical usefulness of compounded bioidentical hormone therapy and recommended limiting it to people with a documented allergy to an approved product or a documented need for a dose or form that is not available [14]. The Menopause Society lists minimal regulation, overdosing and underdosing, impurities and the lack of a label describing risks among its concerns, and says patient preference alone should not decide their use [4]. ACOG recommends FDA-approved hormone therapy over compounded products [15].

Compounded products have no FDA approval. The platforms that mainly sell them are labeled as such in the comparison table.